v ::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::
ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

INCIDENCE OF HEMOPHILUS INFLUENZA AND STREPTOCOCCUS PNEUMONIA IN ACUTE CHRONIC OBSTRUCTIVE AIRWAY DISEASE EXACERBATION AND ITS SENSITIVITY TO LEVOFLOXACIN

AUTHORS:

Dr Muhammad Aslam, Dr Sobia, Dr Awais Hafeez

ABSTRACT:

Aim: To determine the incidence of Streptococcus pneumoniae and Hemophilus influenzae in the acute exacerbation of chronic obstructive pulmonary disease and their sensitivity to levofloxacin. Methods: A cross-sectional study was conducted at the Medicine Unit II of Jinnah Hospital Lahore for one-year duration from April 2019 to April 2020. The study included patients who had already been diagnosed with chronic obstructive pulmonary disease and had symptoms of acute exacerbation and sputum. samples were sent for microbiological evaluation. SPSS 16 was used for statistical analysis. Results: Of the 105 patients in the study, 90 (85.17%) were male. The overall mean age at reporting was 62 ± 10.2 years. S. pneumoniae was isolated from the sputum culture of 33 (31.4%) patients, while 13 (12.4%) patients showed an increase in H. influenzae. Of the 33 S. pneumoniae sputum specimens, 32 (97.0%) were sensitive to levofloxacin and 1 (3.0%) were resistant. All 13 H. influenzae isolates were sensitive to levofloxacin. Conclusion: S. pneumoniae and H. influenzae are still the most common organisms isolated in the acute exacerbation of chronic obstructive pulmonary disease in our population. Levofloxacin is still considered a highly sensitive antibiotic to these common microorganisms in our population, but S. pneumoniae has begun to develop resistance to levofloxacin. Therefore, periodic surveillance of the development of the resistance pattern of common microorganisms to commonly prescribed antibiotics is required. Keywords: COPD, Culture and sensitivity, Sputum, Bacteria.

FULL TEXT

<
Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.